Education
About Us
Working with TipRanks
Follow Us
Genedx Holdings Corp. (WGS)
:WGS
WGS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.45 - $117.75
Previous CloseN/A
Volume338.68K
Average Volume (3M)999.11K
Market Cap
$3.06B
Enterprise Value$2.73B
Total Cash (Recent Filing)$134.56M
Total Debt (Recent Filing)$62.70M
Price to Earnings (P/E)5703.2
Beta1.32
Next Earnings
Nov 17, 2025EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding28,726,248
10 Day Avg. Volume1,289,923
30 Day Avg. Volume999,113
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue7.53
Enterprise Value/Gross Profit11.21
Enterprise Value/Ebitda191.71
Forecast
1Y Price Target
$109.57Price Target Upside1.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
EarningsTest volume beat expectations, price was significantly ahead of forecasts, and EBIT margins exceeded predictions.
Market ExpansionNew guidelines from the AAP now recommend exome/genome as a first-line test for kids with development delay & intellectual disability, opening a big opportunity for WGS to access general pediatricians.
Product LaunchThe ultra-rapid genome was launched, offering a fast turnaround time and competitive pricing, which may help take volumes from smaller competitors.
Bears Say
Stock PerformanceWhile Q1 exome/genome revenue grew 62% Y/Y, the stock sold off by >50% due to perceived sequential slowdown.
Volume EstimatesLowering volume estimates for Q2 and Q3 by 1% due to caution after a volume miss in Q1.
GeneDx Holdings News
WGS FAQ
What was Genedx Holdings Corp.’s price range in the past 12 months?
Genedx Holdings Corp. lowest stock price was $28.45 and its highest was $117.75 in the past 12 months.
What is Genedx Holdings Corp.’s market cap?
Genedx Holdings Corp.’s market cap is $3.06B.
When is Genedx Holdings Corp.’s upcoming earnings report date?
Genedx Holdings Corp.’s upcoming earnings report date is Nov 17, 2025 which is in 102 days.
How were Genedx Holdings Corp.’s earnings last quarter?
Genedx Holdings Corp. released its earnings results on Jul 29, 2025. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.116 by $0.384.
Is Genedx Holdings Corp. overvalued?
According to Wall Street analysts Genedx Holdings Corp.’s price is currently Undervalued.
Does Genedx Holdings Corp. pay dividends?
Genedx Holdings Corp. does not currently pay dividends.
What is Genedx Holdings Corp.’s EPS estimate?
Genedx Holdings Corp.’s EPS estimate is 0.36.
How many shares outstanding does Genedx Holdings Corp. have?
Genedx Holdings Corp. has 28,726,248 shares outstanding.
What happened to Genedx Holdings Corp.’s price movement after its last earnings report?
Genedx Holdings Corp. reported an EPS of $0.5 in its last earnings report, beating expectations of $0.116. Following the earnings report the stock price went up 8.091%.
Which hedge fund is a major shareholder of Genedx Holdings Corp.?
Currently, no hedge funds are holding shares in WGS
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.57 (1.13% Upside)
$109.57 (1.13% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 186.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
278.39%
12-Months-Change
Fundamentals
Return on Equity
0.60%
Trailing 12-Months
Asset Growth
19.21%
Trailing 12-Months
Company Description
Genedx Holdings Corp.
GeneDx Holdings (WGS) is a pioneering company in the field of genomics, focused on providing advanced genetic testing and analysis. Operating primarily within the biotechnology and healthcare sectors, GeneDx offers comprehensive genomic services that include whole genome sequencing, exome sequencing, and specialized genetic testing solutions. The company's services are aimed at healthcare providers, researchers, and patients seeking to understand genetic conditions, with the goal of enabling personalized medicine and better clinical outcomes.
WGS Company Deck
WGS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with GeneDx achieving record revenue and significant growth in exome and genome testing. The company improved its reimbursement rates and expanded into new markets. Although there are challenges related to new indications and the slower adoption of testing in general pediatrics, the overall outlook remains strong with raised revenue guidance and sustained profitability.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$109.57
▲(1.13% Upside)
Technical Analysis
Ownership Overview
60.46% Insiders
17.25% Mutual Funds
0.40% Other Institutional Investors
13.60% Public Companies and Individual Investors